<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>FML- fluorometholone suspension/ drops </strong><br>Allergan, Inc.<br></p></div>
<h1>FML<span class="Sup">®</span><br>(fluorometholone ophthalmic suspension, USP) 0.1%
</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="dcl-dpl"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s1"></a><a name="section-1"></a><p></p>
<p class="First">sterile
</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s2"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION
</h1>
<p class="First"><span class="Bold">FML<span class="Sup">®</span></span> (fluorometholone ophthalmic suspension, USP) 0.1% is a sterile, topical anti-inflammatory agent for ophthalmic use.
</p>
<p><span class="Bold">Chemical Name</span></p>
<p>Fluorometholone: 9-Fluoro-11β,17-dihydroxy-6α-methylpregna-1,4-diene-3,20-dione.
</p>
<p><span class="Bold">Structural Formula</span></p>
<p><a name="f1"></a><img alt="Structural Formula
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c374d65a-35b5-4c9e-9069-5148875dc4df&amp;name=structuralformula.jpg"></p>
<p><span class="Bold">Contains</span></p>
<p><span class="Bold">Active:</span> fluorometholone 0.1%. <span class="Bold">Preservative:</span> benzalkonium chloride 0.004%. <span class="Bold">Inactives:</span> edetate disodium; polysorbate 80; polyvinyl alcohol 1.4%; purified water; sodium chloride; sodium phosphate, dibasic; sodium phosphate, monobasic; and sodium hydroxide to adjust pH. <span class="Bold">FML<span class="Sup">®</span></span> suspension is formulated with a pH from 6.2 to 7.5. It has an <span class="product-label-link" type="condition" conceptid="4197115" conceptname="Osmotic pressure">osmolality</span> range of 290-350 mOsm/kg.
</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="s5"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY
</h1>
<p class="First">Corticosteroids inhibit the inflammatory response to a variety of inciting agents and probably delay or slow healing. They inhibit the <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, fibrin deposition, capillary dilation, leukocyte migration, capillary proliferation, fibroblast proliferation, deposition of collagen, and <span class="product-label-link" type="condition" conceptid="4050007" conceptname="Scar">scar</span> formation associated with <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>.
</p>
<p>There is no generally accepted explanation for the mechanism of action of ocular corticosteroids. However, corticosteroids are thought to act by the induction of phospholipase A<span class="Sub">2</span> inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> such as prostaglandins and leukotrienes by inhibiting the release of their common precursor, arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A<span class="Sub">2</span>.
</p>
<p>Corticosteroids are capable of producing a rise in intraocular pressure. In clinical studies of documented steroid-responders, fluorometholone demonstrated a significantly longer average time to produce a rise in intraocular pressure than dexamethasone phosphate; however, in a small percentage of individuals, a significant rise in intraocular pressure occurred within one week. The ultimate magnitude of the rise was equivalent for both drugs.
</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s6"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE
</h1>
<p class="First"><span class="Bold">FML<span class="Sup">®</span></span> suspension is indicated for the treatment of corticosteroid-responsive <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe.
</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s7"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS
</h1>
<p class="First"><span class="Bold">FML<span class="Sup">®</span></span> suspension is contraindicated in most viral diseases of the cornea and conjunctiva, including epithelial <span class="product-label-link" type="condition" conceptid="373404" conceptname="Ophthalmic herpes simplex">herpes simplex keratitis</span> (<span class="product-label-link" type="condition" conceptid="373404" conceptname="Ophthalmic herpes simplex">dendritic keratitis</span>), <span class="product-label-link" type="condition" conceptid="140633" conceptname="Vaccinia">vaccinia</span>, and <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">varicella</span>, and also in <span class="product-label-link" type="condition" conceptid="4009326" conceptname="Mycobacterial infection">mycobacterial infection</span> of the eye, and fungal diseases of ocular structures.
</p>
<p><span class="Bold">FML<span class="Sup">®</span></span> suspension is also contraindicated in individuals with known or suspected <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any of the ingredients of this preparation and to other corticosteroids.
</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="s8"></a><a name="section-6"></a><p></p>
<h1>WARNINGS
</h1>
<p class="First">Prolonged use of corticosteroids may increase intraocular pressure in susceptible individuals, resulting in <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> with damage to the optic nerve, defects in visual acuity and fields of vision, and in <span class="product-label-link" type="condition" conceptid="375256" conceptname="Anterior subcapsular polar senile cataract">posterior subcapsular cataract</span> formation. Prolonged use may also suppress the host immune response and thus increase the hazard of secondary ocular <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.
</p>
<p>Various ocular diseases and long-term use of topical corticosteroids have been known to cause corneal and <span class="product-label-link" type="condition" conceptid="4088088" conceptname="Scleral thinning">scleral thinning</span>. Use of topical corticosteroids in the presence of thin corneal or scleral tissue may lead to perforation.
</p>
<p>Acute purulent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> of the eye may be masked or activity enhanced by the presence of corticosteroid medication.
</p>
<p>If this product is used for 10 days or longer, intraocular pressure should be routinely monitored even though it may be difficult in children and uncooperative patients. Steroids should be used with caution in the presence of <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>. Intraocular pressure should be checked frequently.
</p>
<p>The use of steroids after <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span> surgery may delay healing and increase the incidence of bleb formation.
</p>
<p>Use of ocular steroids may prolong the course and may exacerbate the severity of many <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> of the eye (including herpes simplex). Employment of a corticosteroid medication in the treatment of patients with a history of herpes simplex requires great caution; frequent slit lamp microscopy is recommended.
</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="s9"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS
</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="s10"></a><a name="section-7.1"></a><p></p>
<h2>General
</h2>
<p class="First">The initial prescription and renewal of the medication order beyond 20 milliliters of <span class="Bold">FML<span class="Sup">®</span></span> suspension should be made by a physician only after examination of the patient with the aid of magnification, such as slit lamp biomicroscopy and, where appropriate, fluorescein staining. If signs and symptoms fail to improve after two days, the patient should be re-evaluated.
</p>
<p>As <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span> of the cornea are particularly prone to develop coincidentally with long-term local corticosteroid applications, fungal invasion should be suspected in any persistent <span class="product-label-link" type="condition" conceptid="373202" conceptname="Corneal ulcer">corneal ulceration</span> where a corticosteroid has been used or is in use. Fungal cultures should be taken when appropriate.
</p>
<p>If this product is used for 10 days or longer, intraocular pressure should be monitored (see <a href="#s8">WARNINGS</a>).
</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="s11"></a><a name="section-7.2"></a><p></p>
<h2>Information for Patients
</h2>
<p class="First">If <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> persists longer than 48 hours or becomes aggravated, the patient should be advised to discontinue use of the medication and consult a physician.
</p>
<p>This product is sterile when packaged. To prevent contamination, care should be taken to avoid touching the bottle tip to eyelids or to any other surface. The use of this bottle by more than one person may spread <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. Keep bottle tightly closed when not in use. Keep out of the reach of children.
</p>
<p>The preservative in <span class="Bold">FML<span class="Sup">®</span></span> suspension, benzalkonium chloride, may be absorbed by soft contact lenses. Patients wearing soft contact lenses should be instructed to wait at least 15 minutes after instilling <span class="Bold">FML<span class="Sup">®</span></span> suspension to insert soft contact lenses.
</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="s12"></a><a name="section-7.3"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility 
</h2>
<p class="First">No studies have been conducted in animals or in humans to evaluate the possibility of these effects with fluorometholone.
</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="s13"></a><a name="section-7.4"></a><p></p>
<h2>Pregnancy
</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="s14"></a><a name="section-7.4.1"></a><p></p>
<p class="First"><span class="Bold">Teratogenic effects. Pregnancy Category C</span></p>
<p>Fluorometholone has been shown to be embryocidal and teratogenic in rabbits when administered at low multiples of the human ocular dose. Fluorometholone was applied ocularly to rabbits daily on days 6-18 of gestation, and dose-related fetal loss and fetal abnormalities including <span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palate</span>, deformed rib cage, anomalous limbs and neural abnormalities such as <span class="product-label-link" type="condition" conceptid="432419" conceptname="Encephalocele">encephalocele</span>, craniorachischisis, and <span class="product-label-link" type="condition" conceptid="4283381" conceptname="Spina bifida">spina bifida</span> were observed. There are no adequate and well-controlled studies of fluorometholone in pregnant women, and it is not known whether fluorometholone can cause fetal harm when administered to a pregnant woman. Fluorometholone should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="s15"></a><a name="section-7.5"></a><p></p>
<h2>Nursing Mothers
</h2>
<p class="First">It is not known whether topical ophthalmic administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in human milk. Systemically‑administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. Because of the potential for serious adverse reactions in nursing infants from fluorometholone, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s16"></a><a name="section-7.6"></a><p></p>
<h2>Pediatric Use
</h2>
<p class="First">Safety and effectiveness in infants below the age of two years have not been established.
</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="s17"></a><a name="section-7.7"></a><p></p>
<h2>Geriatric Use
</h2>
<p class="First">No overall differences in safety or effectiveness have been observed between elderly and younger patients.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s18"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS
</h1>
<p class="First">Adverse reactions include, in decreasing order of frequency, elevation of intraocular pressure (IOP) with possible development of <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> and infrequent optic <span class="product-label-link" type="condition" conceptid="381732" conceptname="Nerve injury">nerve damage</span>, <span class="product-label-link" type="condition" conceptid="375256" conceptname="Anterior subcapsular polar senile cataract">posterior subcapsular cataract</span> formation, and delayed <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> healing.
</p>
<p>Although systemic effects are extremely uncommon, there have been rare occurrences of systemic <span class="product-label-link" type="condition" conceptid="195212" conceptname="Hypercortisolism">hypercorticoidism</span> after use of topical dermatologic steroids applied to the skin.
</p>
<p>Corticosteroid-containing preparations have also been reported to cause acute <span class="product-label-link" type="condition" conceptid="434926" conceptname="Iridocyclitis">anterior uveitis</span> and perforation of the globe. <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">Keratitis</span>, <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="373202" conceptname="Corneal ulcer">corneal ulcers</span>, <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span>, <span class="product-label-link" type="condition" conceptid="377283" conceptname="Conjunctival hyperemia">conjunctival hyperemia</span>, loss of accommodation and <span class="product-label-link" type="condition" conceptid="373194" conceptname="Paralytic ptosis">ptosis</span> have occasionally been reported following local use of corticosteroids.
</p>
<p>The development of secondary ocular <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> (bacterial, fungal and viral) has occurred. Fungal and <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> of the cornea are particularly prone to develop coincidentally with long-term applications of steroids. The possibility of fungal invasion should be considered in any persistent <span class="product-label-link" type="condition" conceptid="373202" conceptname="Corneal ulcer">corneal ulceration</span> where steroid treatment has been used (see <a href="#s8">WARNINGS</a>).
</p>
<p>Transient burning and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">stinging</span> upon instillation and other minor symptoms of ocular irritation have been reported with the use of <span class="Bold">FML<span class="Sup">®</span></span> suspension. Other adverse events reported with the use of fluorometholone include: <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>; foreign body sensation; <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> of eyelid; <span class="product-label-link" type="condition" conceptid="374950" conceptname="Edema of eyelid">eyelid edema</span>/<span class="product-label-link" type="condition" conceptid="381299" conceptname="Swelling of structure of eye">eye swelling</span>; <span class="product-label-link" type="condition" conceptid="4080696" conceptname="Discharge from eye">eye discharge</span>; <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">eye pain</span>; <span class="product-label-link" type="condition" conceptid="4254270" conceptname="Itching of eye">eye pruritus</span>; <span class="product-label-link" type="condition" conceptid="435553" conceptname="Epiphora">lacrimation increased</span>; <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>; <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">taste perversion</span>; <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbance</span> (<span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurry vision</span>); and <span class="product-label-link" type="condition" conceptid="377286" conceptname="Visual field defect">visual field defect</span>. 
</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s19"></a><a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION
</h1>
<p class="First"><span class="Bold">Shake well before using.</span> Instill one drop into the conjunctival sac two to four times daily. During the initial 24 to 48 hours, the dosing frequency may be increased to one application every four hours. Care should be taken not to discontinue therapy prematurely.
</p>
<p>If signs and symptoms fail to improve after two days, the patient should be re-evaluated (see <a href="#s9">PRECAUTIONS</a>).
</p>
<p>The dosing of <span class="Bold">FML<span class="Sup">®</span></span> suspension may be reduced, but care should be taken not to discontinue therapy prematurely. In chronic conditions, withdrawal of treatment should be carried out by gradually decreasing the frequency of applications.
</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s20"></a><a name="section-10"></a><p></p>
<h1>HOW SUPPLIED
</h1>
<p class="First"><span class="Bold">FML<span class="Sup">®</span></span> (fluorometholone ophthalmic suspension, USP) 0.1% is supplied sterile in opaque white LDPE plastic bottles with white high impact polystyrene (HIPS) caps as follows:
</p>
<p>     5 mL in 10 mL bottle NDC 11980-211-05<br>   10 mL in 15 mL bottle NDC 11980-211-10
</p>
<div class="Section" data-sectionCode="44425-7">
<a name="s22"></a><a name="section-10.1"></a><p></p>
<p class="First"><span class="Bold">Storage:</span> Store at 2°-25°C (36°-77°F); protect from freezing. Store in an upright position. 
                    </p>
<p><span class="Bold">Revised: 02/2013</span></p>
<br><p>© 2013 Allergan, Inc.<br>Irvine, CA 92612, U.S.A.<br>® marks owned by Allergan, Inc.<br>Made in the U.S.A.
</p>
<p><a name="f02"></a><img alt="Logo
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c374d65a-35b5-4c9e-9069-5148875dc4df&amp;name=allerganlogo.jpg"></p>
<p>71598US11
</p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s21"></a><a name="section-11"></a><p></p>
<p class="First"><span class="Bold">ALLERGAN</span></p>
<p>NDC 11980-211-05<br><span class="Bold">Rx only</span></p>
<p><span class="Bold">FML<span class="Sup">®</span></span><br>(fluorometholone<br>ophthalmic<br>suspension, USP)<br>0.1%<br>sterile
</p>
<p><span class="Bold">5 mL</span></p>
<div class="Figure">
<a name="f03"></a><img alt="Carton
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c374d65a-35b5-4c9e-9069-5148875dc4df&amp;name=carton.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>FML 		
					</strong><br><span class="contentTableReg">fluorometholone suspension/ drops</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:11980-211</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">OPHTHALMIC</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>fluorometholone</strong> (fluorometholone) </td>
<td class="formItem">fluorometholone</td>
<td class="formItem">1 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>benzalkonium chloride</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>edetate disodium</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>polysorbate 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>polyvinyl alcohol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>water</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium chloride</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium phosphate, dibasic</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium phosphate, monobasic</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium hydroxide</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:11980-211-05</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">5 mL in 1 BOTTLE, DROPPER</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:11980-211-10</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">10 mL in 1 BOTTLE, DROPPER</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA016851</td>
<td class="formItem">02/01/1972</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Allergan, Inc.
							(144796497)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Allergan, Inc.</td>
<td class="formItem"></td>
<td class="formItem">362898611</td>
<td class="formItem">MANUFACTURE(11980-211)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 2/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>d839481e-c5e5-442b-85f7-c634d50b97b9</div>
<div>Set id: c374d65a-35b5-4c9e-9069-5148875dc4df</div>
<div>Version: 5</div>
<div>Effective Time: 20130213</div>
</div>
</div> <div class="DistributorName">Allergan, Inc.</div></p>
</body></html>
